title: [Polymyositis induced or associated with lipid-lowering drugs: five cases].
abstract: OBJECTIVE
  Rhabdomyolysis and myositis are rare, dose-related complications of statins and fenofibrates. The outcome is favorable as a rule with rapid regression after stopping the responsible drug. Recently, various auto-immune disease with evidence of hypersensitivity to HMG-CoA reductase inhibitors or fibrates drugs have been reported. Less than ten cases of dermatomyositis and polymyositis due to cholesterol-lowering drugs (CLD) have been previously reported. Five more cases polymyositis associated with CLD are reported.
  
  
  METHODS
  Symptoms were compatible with diagnosis of polymyositis according to Bohan and Peter and with previous reported criteria for drug-induced myopathy in all cases. None of these patients had previous other connective tissue disorders.
  
  
  RESULTS
  Five patients (median age 68 [54-78], female N =4) with CLD treatment (statin N =4, fenofibrates N =1) have developed iatrogenic polymyositis. All of them presented both proximal muscular weakness and increased muscle enzyme levels. One patient had iatrogenic antisynthetase syndrome characterized by mechanic's hand, Raynaud's phenomenon and anti JO1 antibodies. One other had sclerodermic hand oedema. Antinuclear antibodies were positive in 4 cases and muscle biopsy revealed polymyositis infiltrate in 4 cases. CLD treatment was discontinued with partial clinical improvement in 3 cases. Clinical remission was obtained with corticosteroid (N =5) in association with immunosuppresive agents in 3 cases.
  
  
  CONCLUSIONS
  Muscular symptoms in patient with CLD treatment could be the first symptom of a polymyositis revealed or increased by this treatment and must encourage physician with antinuclear antibodies screening especially in case of proximal muscular weakness and increased muscle enzyme levels.
authors.affiliation: Service de médecine interne A, CHU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France. alfauchais@caramail.com
authors.forename: A-L
authors.initials: AL
authors.lastname: Fauchais
authors.forename: J
authors.initials: J
authors.lastname: Iba Ba
authors.forename: P
authors.initials: P
authors.lastname: Maurage
authors.forename: X
authors.initials: X
authors.lastname: Kyndt
authors.forename: D
authors.initials: D
authors.lastname: Bataille
authors.forename: E
authors.initials: E
authors.lastname: Hachulla
authors.forename: D
authors.initials: D
authors.lastname: Parent
authors.forename: V
authors.initials: V
authors.lastname: Queyrel
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: U
authors.initials: U
authors.lastname: Michon Pasturel
authors.forename: P-Y
authors.initials: PY
authors.lastname: Hatron
authors.forename: P
authors.initials: P
authors.lastname: Vanhille
authors.forename: B
authors.initials: B
authors.lastname: Devulder
mesh_terms: D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017285:Polymyositis / Q000139:chemically induced*
chemical_list: D000974:Antibodies, Antinuclear; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011345:Fenofibrate